These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11342095)

  • 41. Prophylaxis of deep vein thrombosis in total hip replacement: which heparin and what duration?
    Chaouat A; Weitzenblum E
    Respiration; 1998; 65(5):345-6. PubMed ID: 9782215
    [No Abstract]   [Full Text] [Related]  

  • 42. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty.
    Mantilla CB; Horlocker TT; Schroeder DR; Berry DJ; Brown DL
    Anesthesiology; 2003 Sep; 99(3):552-60; discussion 5A. PubMed ID: 12960538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience.
    Hull RD
    Haemostasis; 2000; 30 Suppl 2():95-100; discussion 82-3. PubMed ID: 11251350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
    Dorr LD; Gendelman V; Maheshwari AV; Boutary M; Wan Z; Long WT
    J Bone Joint Surg Am; 2007 Dec; 89(12):2648-57. PubMed ID: 18056497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preoperative Versus Postoperative Initiation of Warfarin Therapy in Patients Undergoing Total Hip and Knee Arthroplasty.
    Cipriano C; Erdle N; Li K; Curtin B
    Orthop Clin North Am; 2017 Jan; 48(1):9-13. PubMed ID: 27886686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group.
    Adolf J; Fritsche HM; Haas S; Hennig FF; Horbach T; Kastl S; Koppenhagen K; Michaelis HC; Rhamanzadeh R; Summa W; Wagner W; Weber U; Wolf H
    Int Angiol; 1999 Jun; 18(2):122-6. PubMed ID: 10424367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
    Leyvraz PF; Bachmann F; Hoek J; Büller HR; Postel M; Samama M; Vandenbroek MD
    BMJ; 1991 Sep; 303(6802):543-8. PubMed ID: 1655136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.
    Eikelboom JW; Quinlan DJ; Douketis JD
    Lancet; 2001 Jul; 358(9275):9-15. PubMed ID: 11454370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.
    Levin LA; Bergqvist D
    Pharmacoeconomics; 2001; 19(5 Pt 2):589-97. PubMed ID: 11465303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients.
    Chibbaro S; Tacconi L
    Surg Neurol; 2008 Aug; 70(2):117-21; discussion 121. PubMed ID: 18262633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Low-molecular-weight heparin for preventing deep-vein thrombosis after total joint arthroplasty].
    Yang G; Lu H; Gao J; Kou B; Yuan Y; Xu B
    Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):25-7. PubMed ID: 11831980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.
    Chapman TM; Goa KL
    Drugs; 2003; 63(21):2357-77. PubMed ID: 14524738
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin.
    Colwell CW; Froimson MI; Mont MA; Ritter MA; Trousdale RT; Buehler KC; Spitzer A; Donaldson TK; Padgett DE
    J Bone Joint Surg Am; 2010 Mar; 92(3):527-35. PubMed ID: 20194309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
    Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
    Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
    Heit JA; Elliott CG; Trowbridge AA; Morrey BF; Gent M; Hirsh J
    Ann Intern Med; 2000 Jun; 132(11):853-61. PubMed ID: 10836911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
    Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
    Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.
    Lavau-Denes S; Lacroix P; Maubon A; Preux PM; Genet D; Vénat-Bouvet L; Labourey JL; Martin J; Slaouti P; Tubiana-Mathieu N
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):65-73. PubMed ID: 23636449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.